Eyenovia Deferred Revenue 2011-2026 | EYEN

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Quarterly Deferred Revenue Eyenovia

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10 M	10 M	12 M	14 M	14 M	14 M	14 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
14 M	10 M	12.6 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	86.5 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	563 K	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	15.9 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	124 K	-	2.54 %	$ 160 B	France
Midatech Pharma plc MTP	1.3 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.69 M	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	227 K	-	-24.86 %	$ 820 K	USA
DBV Technologies S.A. DBVT	3.2 M	$ 20.13	-1.13 %	$ 2.81 B	France
Alterity Therapeutics Limited ATHE	33.3 K	$ 3.65	1.3 %	$ 8.78 B	Australia
Advaxis ADXS	165 K	-	-9.65 %	$ 45.9 M	USA
Dyadic International DYAI	1.73 M	$ 0.87	-	$ 31.5 M	USA
Adverum Biotechnologies ADVM	1.85 M	-	-	$ 86.2 M	USA
Aytu BioScience AYTU	339 K	$ 2.57	-3.57 %	$ 16.1 M	USA
Equillium EQ	15.7 M	$ 2.04	1.24 %	$ 117 M	USA
Aeterna Zentaris AEZS	2.19 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	283 K	-	-10.17 %	$ 12.2 K	USA
Fate Therapeutics FATE	381 K	$ 1.13	-5.04 %	$ 134 M	USA
Aeglea BioTherapeutics AGLE	517 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	6.3 M	-	-	$ 26.5 M	USA
Fennec Pharmaceuticals FENC	248 K	$ 6.14	-4.36 %	$ 175 M	USA
Foghorn Therapeutics FHTX	43.2 M	$ 4.74	-2.87 %	$ 299 M	USA
AIkido Pharma AIKI	957 K	-	1.93 %	$ 17.4 M	USA
Amicus Therapeutics FOLD	8.5 M	$ 14.46	0.03 %	$ 4.46 B	USA
Fulcrum Therapeutics FULC	934 K	$ 7.55	-3.58 %	$ 478 K	USA
Galectin Therapeutics GALT	200 K	$ 2.25	-12.3 %	$ 144 M	USA
CureVac N.V. CVAC	158 M	-	-	$ 867 M	Germany
BioNTech SE BNTX	300 M	$ 87.65	-3.98 %	$ 27.2 B	Germany
Gilead Sciences GILD	202 M	$ 138.19	-1.38 %	$ 172 B	USA
Coherus BioSciences CHRS	1.96 M	$ 1.61	-3.59 %	$ 189 M	USA
Galmed Pharmaceuticals Ltd. GLMD	538 K	$ 0.54	4.26 %	$ 503 K	Israel
Genmab A/S GMAB	26 M	$ 27.01	-2.67 %	$ 17.2 B	Danmark
Alnylam Pharmaceuticals ALNY	4.84 M	$ 314.44	-4.81 %	$ 41.2 B	USA
Gossamer Bio GOSS	20 M	$ 0.32	-7.11 %	$ 73.1 M	USA
Grifols, S.A. GRFS	30.1 M	$ 7.91	-3.95 %	$ 6.83 B	Spain
Alpine Immune Sciences ALPN	35.6 M	-	-	$ 2.17 B	USA
AlloVir ALVR	2.66 M	-	4.14 %	$ 49.1 M	USA
Halozyme Therapeutics HALO	1.75 M	$ 63.51	0.68 %	$ 7.61 B	USA